Biotechs developing a class of novel cancer drugs called anti-TIGIT therapies turned lower in the premarket Friday after a similar drug developed by Roche (OTCQX:RHHBY) failed in a Phase 2/3 clinical ...
Source LinkBiotechs developing a class of novel cancer drugs called anti-TIGIT therapies turned lower in the premarket Friday after a similar drug developed by Roche (OTCQX:RHHBY) failed in a Phase 2/3 clinical ...
Source Link
Comments